Below are current clinical trials.2 studies in Spinal Cord Injury Rehabilitation Program in Minnesota
(open studies only).
Filter this list of studies by location, status and more.
The aim of this study is to evaluate efficacy and safety of riluzole in the treatment of patients with acute SCI. The primary objective is to evaluate the superiority of riluzole, at a dose of 2 x 100 mg the first 24 hours followed by 2 x 50 mg for the following 13 days after injury, as compared to placebo, in change between 180 days and baseline in motor outcomes as measured by International Standards for Neurological Classification of Spinal Cord Injury Examination (ISNCSCI) Motor Score, in patients with acute traumatic SCI, presenting to the hospital less than 12 hours after injury. Secondary objectives are to evaluate the effects of riluzole on overall neurologic recovery, sensory recovery, functional outcomes, quality of life outcomes, health utilities, mortality, and adverse events. The working hypothesis is that the riluzole treated subjects will experience superior motor, sensory, functional, and quality of life outcomes as compared to those receiving placebo, with an acceptable safety profile.
This will be a prospective registry conducted and maintained at Mayo Clinic Rochester from which collaborating sites within Mayo, Mayo Health Systems, and other spinal cord injury centers can draw from in order to fulfill research enrollment.The purpose is to generate data from this group of subjects pertaining to physical activities and the secondary consequences of using a wheelchair, to allow future research on preventative measures to aid in a better quality of life within this population.